Skip to main content
SpringerLink
Log in

One dose to treat them all? – Therapeutisches Drug Monitoring zur Dosisoptimierung in der oralen Antitumortherapie

One dose to treat them all? Therapeutic drug monitoring for dose optimization in oral anticancer treatment

  • Onkologische Pharmazie
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Groenland SL, Mathijssen RHJ, Beijnen JH et al (2019) Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur J Clin Pharmacol 75:1309–1318

    Article  PubMed  Google Scholar 

  2. Mathijssen RHJ, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11:272–281

    Article  CAS  PubMed  Google Scholar 

  3. McLaughlin AM, Schmulenson E, Teplytska O et al (2021) Developing a nationwide infrastructure for therapeutic drug monitoring of targeted oral anticancer drugs: The ON-TARGET study protocol. Cancers 13:1–15

    Google Scholar 

  4. Mueller-Schoell A, Groenland SL, Scherf-Clavel O et al (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77:441–464

    Article  PubMed  Google Scholar 

  5. Touw DJ, Neef C, Thomson AH, Vinks AA et al (2005) Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 27:10–17

    Article  CAS  PubMed  Google Scholar 

  6. Yu H, Steeghs N, Nijenhuis CM et al (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 53:305–325

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. Klinische Pharmazie, Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität Bonn, An der Immenburg 4, 53121, Bonn, Deutschland

    O. Teplytska, N. Haas &  U. Jaehde

  2. Abt. Klinische Pharmazie & Biochemie, Institut für Pharmazie, Freie Universität Berlin, Berlin, Deutschland

    F. Klima & C. Kloft

  3. Graduiertenprogramm PharMetrX, Berlin/Potsdam, Deutschland

    F. Klima

Authors
  1. O. Teplytska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Klima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Kloft
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Jaehde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Jaehde.

Ethics declarations

Interessenkonflikt

C. Kloft erhält Forschungsunterstützungen von einem Industriekonsortium (Fa. AbbVie Deutschland GmbH & Co. KG, Fa. AstraZeneca, Fa. Boehringer Ingelheim Pharma GmbH & Co. KG, Fa. F. Hoffmann-La Roche Ltd, Fa. Merck KGaA, Fa. Novo Nordisk A/S und Fa. Sanofi) für das Graduiertenprogramm PharMetrX. O. Teplytska, F. Klima, N. Haas und U. Jaehde geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

O. Teplytska und F. Klima teilen sich die Erstautorenschaft; C. Kloft und U. Jaehde teilen sich die Seniorautorenschaft.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teplytska, O., Klima, F., Haas, N. et al. One dose to treat them all? – Therapeutisches Drug Monitoring zur Dosisoptimierung in der oralen Antitumortherapie. best practice onkologie 18, 258–261 (2023). https://doi.org/10.1007/s11654-023-00486-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-023-00486-9

Search

Navigation